Sumanta K. Pal: Plenty of terrific microbiome based presentations at ESMO24

Sumanta K. Pal shared a post on X:

”While I’ve been principally focused on genitourinary abstracts at ESMO24, it’s worth noting that there are plenty of terrific microbiome based presentations.

On Saturday in the Valencia room, Bertrand Routy (who will be visiting City of Hope with Arielle Elkrief  for a special symposium in October!) will be leading a session including Maria Rescigno and Jan Theys.

On Monday, Marios Giannakis from Dana-Farber will discuss implications in colon cancer.

Of course, can’t wait to see data from Chiara Ciccarese on axitinib/pembrolizumab plus fecal microbiota transplantation in kidney cancer – LBA77!”

Vivek Subbiah shared a post by Sumanta K. Pal, on X, adding:

”Manipulating the microbiome has huge potential in oncology and the field is just opening up. Terrific educational session and special symposium at ESMO24.”

Source: Sumanta K. Pal/X and Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.

Sumanta (Monty) Pal, MD, is a medical oncologist and an expert in genitourinary cancers at the City of Hope Comprehensive Cancer Center in Los Angeles. He serves as the Vice Chair of Academic Affairs, Professor and co-director of the Kidney Cancer Program and leads the Kidney and Bladder Cancer Disease Team at City of Hope. He specialises in kidney, bladder, and prostate cancers.